Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis

Published:2023-01-11 Issue:1 Volume:38 Page:
ISSN:1432-1262
Container-title:International Journal of Colorectal Disease
language:en
Short-container-title:Int J Colorectal Dis

Author:

Amonkar Mayur M.,Abderhalden Lauren A.,Frederickson Andrew M.,Aksomaityte Audrone,Lang Brian M.,Leconte Pierre,Zhang Ina

Funder

Merck Sharp & Dohme

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s00384-022-04301-9.pdf

Reference90 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3)209–249. https://doi.org/10.3322/caac.21660

2. National Cancer Institute SEER cancer stat facts: colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 24 June 2021

3. Cutsem EV, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011–2019. https://doi.org/10.1200/jco.2010.33.5091

4. Tol J, Nagtegaal ID, Punt CJA (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361(1):98–99. https://doi.org/10.1056/NEJMc0904160

5. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Krüger S, Becker T, Röcken C (2014) HER2/neu testing in primary colorectal carcinoma, (in eng). Br J Cancer 111(10):1977–1984. https://doi.org/10.1038/bjc.2014.483

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression;Acta Pharmaceutica Sinica B;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3